Cell Reprogramming Market

Cell Reprogramming Market Overview

The cell reprogramming market is estimated to be worth $1.16 billion in 2020 and is expected to grow at compounded annual growth rate (CAGR) of 8% during the forecast period. Over the years, advances in stem cell biology and regenerative medicine have enabled the discovery and development of a number of stem cell-based therapies. In fact, many believe that such interventions possess the potential to address several unmet needs related to the treatment of a wide range of diseases. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, effectively reversing the adverse physiological effects they cause. However, challenges, such as scarcity of healthy stem cell donors, adverse immunological reactions upon treatment (owing to donor-recipient haplotype mismatches), and a number of ethical concerns related to the use of stem cells, are impeding progress in this field. 

The discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka’s team in 2006 revolutionized stem cell research. Through his Nobel prize winning research, Yamanaka was able to reprogram mature somatic cells into a stem-like (pluripotent) state. This finding not only established the means to synthesize stem cells (thereby, offering a virtually endless supply of research material), but also provided the means to alleviate the social stigma surrounding stem cell research. Presently, cellular reprogramming is perceived as a powerful and versatile tool, with numerous applications in fundamental research and medicine. It is worth mentioning that, today, many experts believe that stem cell therapies may be a possible solution to the COVID-19 pandemic. In fact, there are speculations, based on some evidence, that infected patients treated with stem cells may be more likely to successfully combat the symptoms of the disease. Research has also demonstrated that mesenchymal stem cells have the potential to be effectively used to treat SARS-CoV-2 induced pneumonia. Numerous partnerships have been inked amongst stakeholders in cell reprogramming market, indicative to future growth of the market. Interestingly, start-ups / university spin-offs have been the flagbearers in this upcoming field of therapeutics and are also expected to sustain the research momentum, over the coming years.

Key Companies in Cell Reprogramming Market

Examples of key companies engaged in cell reprogramming market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Allele Biotechnology, ALSTEM, Applied Biological Materials, Axol Bioscience, Creative Bioarray, DefiniGEN, FUJIFILM Cellular Dynamics International, Lonza, Mogrify, REPROCELL, Stemnovate and Thermo Fisher Scientific. This market report includes an easily searchable excel database of all the companies providing cell reprogramming services and products, worldwide.

Recent Developments in Cell Reprogramming Market:

Several recent developments have taken place in the field of cell reprogramming market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In May 2026, Pluristyx entered into a distribution agreement with Qkine in order to enhance induced pluripotent stem cell differentiation workflows. The partnership integrates Pluristyx’s clinical-grade iPSC lines with Qkine’s growth factors to streamline research and manufacturing, improve reproducibility, and accelerate timelines for cell-based therapies and regenerative medicine applications globally.
• In March 2026, Matricelf entered into a collaboration with CiRA Foundation to evaluate scalable manufacturing of iPSC-based engineered neural tissues for spinal cord injury treatment. The agreement focuses on integrating CiRA-derived iPSCs into Matricelf’s platform to enable automated, cost-effective production of regenerative therapies, supporting future commercialization and broader clinical adoption.
• In March 2026, Applied StemCell collaborated with Cellipont Bioservices to streamline iPSC-derived cell therapy development. The partnership connects genome engineering, GMP cell banking, and manufacturing services, aiming to reduce development timelines and technical risks while enabling scalable, regulatory-compliant production from early research through clinical and commercial stages.
• In March 2026, Catalent entered into development and manufacturing agreement with GelMEDIX for iPSC-derived therapies targeting ocular and retinal diseases. GelMEDIX will leverage Catalent’s GMP-compliant iPSC lines and manufacturing capabilities, supporting process development, scale-up, and clinical production to advance regenerative treatments for vision restoration through all development phases.
• In March 2026, erumo Corporation and the CiRA Foundation secured funding from Japan’s AMED to advance automated and standardized iPSC manufacturing.

Scope of the Report

The ‘Cell Reprogramming Market, 2020-2030’ market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the cell reprogramming market. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in cell reprogramming market.

In addition to other elements, the market research report includes: 

• A review of the overall landscape of cell reprogramming market, featuring a list of over 30 cell reprogramming (iPSC Generation) / direct reprogramming service and product providers and a detailed analysis of these providers based on a number of parameters, such as year of establishment, company size, geographical location, location of manufacturing facilities, type of  service (iPSC generation and direct reprogramming), type of offering (in-house development, kit, service, technology (for licensing) and iPSC lines), type of technology (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), type of vector used (viral vector, non-viral vector, mRNA and others), source cell for iPSC generation (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), target indication(s), type of application (research and therapeutic) and additional service(s) offered (assay development, cell and tissue sourcing, cell banking, cell characterization, cell differentiation, cell sequencing, genome editing and other services).  
• An insightful competitiveness analysis of iPSC generation and direct reprogramming service providers, based on supplier strength (based on a company’s employee count and years of experience) and service strength (which takes into account the number of reprogramming technologies offered, number of source cells used for iPSC generation used, number of target indications and number of manufacturing facilities).
• Elaborate profiles of the industry players that offer cell reprogramming services and products. Each profiles features a brief overview of the company, its financial information (if available), details on cell reprogramming approaches, types of cell(s) utilized and differentiated, target indication(s), other drug discovery services offered, recent developments and an informed future outlook. 
• A detailed analysis of more than 540 completed, ongoing and planned clinical studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, study design, current trial status, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials.
• An analysis of the partnerships that have been established in cell reprogramming market since 2016, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, clinical trial agreements, process development agreements, and other relevant deals.
• A list of stem cell therapy developers / manufacturers, generated based on a detailed analysis of a set of relevant parameters (such as company size (employee count), type of cell (s), indication count and existing partnership(s)), which are anticipated to partner with cell reprogramming service and product providers in the foreseen future.

The key objective of cell reprogramming market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for cell reprogramming market during the forecast period. Based on multiple parameters, such as growth of the overall iPSC market, reprogramming cost and annual number of projects for stem cell therapies, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the forecast period, 2020-2030. The market report also features the likely distribution of the current and forecasted opportunity within cell reprogramming services and products market across [A] type of technology offered (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), [B] Source cells for iPSC generation  (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), [C] type of application (research and therapeutic), and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). To account for the uncertainties associated with the development of reprogrammed cells and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the market report were influenced by discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of interviews held with the following industry stakeholders:

• Cristiana Pires (Co-Founder and Chief Executive Officer, Asgard Therapeutics)
• Julien Maruotti (Chief Scientific Officer, Phenocell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.